To evaluate the capacity of combination therapy in vivo, the compounds were evaluated in both an OCI-AML3-derived orthotopic model of AML and a primary patient-derived AML xenograft (PDX) (Figure 6). This evidence concerns the gene RUNX2 and acute myeloid leukemia.